Aminooxyacetic acid hemihydrochloride (Carboxymethoxylamine Hemihydrochloride) (Synonyms: Aminooxyacetate) |
Catalog No.GC34064
One-Click Copy Product Info
|
Aminooxyacetic acid hemihydrochloride (Carboxymethoxylamine Hemihydrochloride) is an inhibitor of the malate-aspartate shuttle (MAS) and γ-aminobutyric acid transaminase (GABA-T).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2921-14-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Aminooxyacetic acid hemihydrochloride (Carboxymethoxylamine Hemihydrochloride) is an inhibitor of the malate-aspartate shuttle (MAS) and γ-aminobutyric acid transaminase (GABA-T). Aminooxyacetic acid hemihydrochloride blocks NADH transfer between mitochondria and the cytoplasm by interfering with malate-aspartate shuttle function. Aminooxyacetic acid hemihydrochloride can be used in studies related to energy metabolism, bioenergetic processes, GABA-related metabolic pathways in the nervous system, and cancer[1-4].
In vitro, Aminooxyacetic acid hemihydrochloride (5mM) treated rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs) for 36 hours. Aminooxyacetic acid hemihydrochloride significantly inhibited the malate-aspartate shuttle in RA-FLSs, thereby inhibiting ASIC1a-mediated migration and invasion of RA-FLSs[5]. Aminooxyacetic acid hemihydrochloride (0.5–2mM) treated RM-1 prostate cancer cells for 24 hours, significantly inhibiting cell proliferation, migration, and invasiveness, while reducing ATP levels and inducing apoptosis[6].
In vivo, Aminooxyacetic acid hemihydrochloride (5mg/kg; every 2 days) was administered intraperitoneally to ovariectomized C57BL/6J mice for 6 weeks. Aminooxyacetic acid hemihydrochloride effectively rescued bone loss[7]. After 16 weeks of N-nitrosodiethylamine/CCl4 treatment, Aminooxyacetic acid hemihydrochloride (5mg/kg; twice a week) was administered intraperitoneally to LKO mice for 16 weeks. Aminooxyacetic acid hemihydrochloride significantly inhibited tumor progression[8].
References:
[1] Wang C, Chen H, Zhang M, et al. Malate-aspartate shuttle inhibitor aminooxyacetic acid leads to decreased intracellular ATP levels and altered cell cycle of C6 glioma cells by inhibiting glycolysis. Cancer Lett. 2016 Aug 1;378(1):1-7.
[2] Pagliusi SR, Gomes C, Leite JR, et al. Aminooxyacetic acid induced accumulation of GABA in the rat brain. Interaction with GABA receptors and distribution in compartments. Naunyn Schmiedebergs Arch Pharmacol. 1983 Apr;322(3):210-5.
[3] Korangath P, Teo WW, Sadik H, et al. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clin Cancer Res. 2015 Jul 15;21(14):3263-73.
[4] Katayama R, Nagata S, Iida H, et al. Possible role of cysteine-S-conjugate β-lyase in species differences in cisplatin nephrotoxicity. Food Chem Toxicol. 2011 Sep;49(9):2053-9.
[5] Hu W, Wang K, Dong Y, et al. RIPK3 promotes ASIC1a-mediated fibroblast-like synoviocyte migration and invasion via malate shuttle-driven mitochondrial respiration in rheumatoid arthritis. Theranostics. 2025 Aug 11;15(17):8719-8737.
[6] Teng H, Yang B, Su Y, et al. Aminooxyacetic acid hemihydrochloride leads to decreased intracellular ATP levels and altered cell cycle of prostate cancer cells by suppressing energy metabolism. Biomed Pharmacother. 2023 Nov;167:115605.
[7] Yang B, Su Y, Han S, et al. Aminooxyacetic acid hemihydrochloride inhibits osteoclast differentiation and bone resorption by attenuating oxidative phosphorylation. Front Pharmacol. 2022 Sep 30;13:980678.
[8] Xiang J, Chen C, Liu R, et al. Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. J Clin Invest. 2021 Apr 15;131(8):e144703.
| Cell experiment [1]: | |
Cell lines | RM-1 cells (mouse prostate cancer cell line) |
Preparation Method | RM-1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) at 37°C, 5% CO₂, and 95% air humidity. RM-1 cells were treated with Aminooxyacetic acid hemihydrochloride (0.5-2mM). |
Reaction Conditions | 0.5–2mM; 24h |
Applications | Aminooxyacetic acid hemihydrochloride significantly inhibited cell proliferation, migration, and invasiveness, decreased ATP levels, increased reactive oxygen species (ROS), halted the cell cycle phase, and triggered apoptosis. Aminooxyacetic acid hemihydrochloride decreased mitochondrial membrane potential and the ability to uptake glucose. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | Mice were ovariectomized (OVX) and, one week later, received intraperitoneal injections of Aminooxyacetic acid hemihydrochloride (5mg/kg) every 2 days for 6 weeks. |
Dosage form | 5mg/kg; i.p.; every 2 days for 6 weeks |
Applications | Aminooxyacetic acid hemihydrochloride treatment effectively rescued bone loss, improved bone parameters (BV/TV, Tb.N, Tb.Sp), decreased serum CTXI level, and inhibited excessive osteoclastogenesis in OVX mice. |
References: | |
| Cas No. | 2921-14-4 | SDF | |
| Synonyms | Aminooxyacetate | ||
| Canonical SMILES | OC(CON)=O.[H]Cl.OC(CON)=O | ||
| Formula | NH2OCH2COOH · 0.5HCl | M.Wt | 109.3 |
| Solubility | DMSO : 42.9 mg/mL (392.50 mM) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 9.1491 mL | 45.7457 mL | 91.4913 mL |
| 5 mM | 1.8298 mL | 9.1491 mL | 18.2983 mL |
| 10 mM | 914.9 μL | 4.5746 mL | 9.1491 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)